Overview

TQB2618 Injection Combined With Penpulimab Injection in the Treatment of Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

Status:
Not yet recruiting

Trial end date:
2024-05-01

Target enrollment:

Participant gender:

Summary

Cohort 1 was a two-phase study design: a phase I dose-exploration study to determine the dose of TQB2618 combined with Penpulimab Injection; Phase II extension study, case expansion based on the dose administered as determined in phase I. The two-phase cohort 1 study enrolled subjects with advanced nasopharyngeal carcinoma who had failed previous platinum-based chemotherapy and immune checkpoint inhibitors (PD-1/PD-L1, etc.).

Phase:

Phase 2

Details

Lead Sponsor:

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Treatments:

Cisplatin
Gemcitabine